Abstract
Non-dipping is a common pattern of arterial hypertension and it is associated with increased cardiovascular risk. Use of ambulatory blood pressure monitoring, as suggested in recent guidelines, could further increase its prevalence among subjects with hypertension. In this review we discuss assessment, relevance and associated factors. Non-dipping could be addressed through chronotherapy, the use of specific classes of anti-hypertensives, such as renin-angiotensin blockers, or modification of associated factors. However, more data are needed in order to comprehensively estimate factors associated with non-dipping and how they could be modified.
Keywords: Arterial hypertension, ambulatory blood pressure monitoring, blood pressure, cardiovascular risk factor, chronotherapy, night time blood pressure, non-dipping.
Current Vascular Pharmacology
Title:Non-dipping Status in Arterial Hypertension: An Overview
Volume: 12 Issue: 3
Author(s): Maria Sarigianni, Konstantinos Dimitrakopoulos and Apostolos Tsapas
Affiliation:
Keywords: Arterial hypertension, ambulatory blood pressure monitoring, blood pressure, cardiovascular risk factor, chronotherapy, night time blood pressure, non-dipping.
Abstract: Non-dipping is a common pattern of arterial hypertension and it is associated with increased cardiovascular risk. Use of ambulatory blood pressure monitoring, as suggested in recent guidelines, could further increase its prevalence among subjects with hypertension. In this review we discuss assessment, relevance and associated factors. Non-dipping could be addressed through chronotherapy, the use of specific classes of anti-hypertensives, such as renin-angiotensin blockers, or modification of associated factors. However, more data are needed in order to comprehensively estimate factors associated with non-dipping and how they could be modified.
Export Options
About this article
Cite this article as:
Sarigianni Maria, Dimitrakopoulos Konstantinos and Tsapas Apostolos, Non-dipping Status in Arterial Hypertension: An Overview, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/157016111203140518173019
DOI https://dx.doi.org/10.2174/157016111203140518173019 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Current Diabetes Reviews Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design
Current Rheumatology Reviews β-sitosterol: Bioactive Compounds in Foods, their Role in Health Promotion and Disease Prevention “A Concise Report of its Phytopharmaceutical Importance”
Current Traditional Medicine ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy Regioselective Synthesis of 2-Chloroquinoline Based Ethyl 4-(3- Hydroxyphenyl)-2,7,7-Trimethyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline-3- Carboxylates and their In-Silico Evaluation Against P. falciparum Lactate Dehydrogenase
Medicinal Chemistry Domperidone and Long QT Syndrome
Current Drug Safety The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic: A Role for Immunophilins in Cellular Signalling in Health and Disease (Guest Editors: Juan Antonio Rosado Dionisio and Pedro Cosme Redondo Liberal)]
Current Medicinal Chemistry SLS-catalyzed Multi-component One-pot Reactions for the Convenient Synthesis of Spiro[indoline-3,4’-pyrano [2,3-c]pyrazole] Derivatives
Current Organocatalysis Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders
Current Drug Metabolism Lifestyle Interventions for Cardiovascular Risk Reduction in Women with Breast Cancer
Current Cardiology Reviews Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1), a Relevant Target for Diabetic Vasculopathy?
Cardiovascular & Hematological Disorders-Drug Targets EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets